While CD19-directed CAR-T therapy has demonstrated transformative potential in R/R DLBCL, its widespread application is limited by factors including toxicity, manufacturing delays, and the requirement for adequate T-cell fitness. Here, CD19 is linked to diffuse large B-cell lymphoma.